Artwork

Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Myelofibrosis — An Interview with Dr Raajit K Rampal on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting

43:18
 
Share
 

Manage episode 477426419 series 1464173
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

Featuring an interview with Dr Raajit K Rampal, including the following topics:

  • Clinical decision-making in the initiation and stopping of systemic therapy for myelofibrosis (MF) (0:00)
  • Novel research strategies involving CDK4/6 inhibitors for MF (8:03)
  • Implications of the JUMP study for clinical practice (10:00)
  • Therapeutic switching strategies with JAK inhibitors for MF (12:17)
  • Clinical rationale for the use of luspatercept and elritercept for MF (15:35)
  • Emerging clinical data involving BET inhibitors for MF (16:57)
  • Tolerability concerns with selinexor in patients with MF (20:01)
  • Mechanism of and clinical data with the MDM2 inhibitor navtemadlin for MF (22:32)
  • Additional novel strategies under clinical investigation for MF (25:52)
  • Potential transformation of myeloproliferative neoplasms to acute myeloid leukemia (29:40)
  • Management of polycythemia vera and essential thrombocythemia (34:27)
  • General management principles for myeloproliferative neoplasms (37:53)

CME information and select publications

  continue reading

1554 episodes

Artwork
iconShare
 
Manage episode 477426419 series 1464173
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

Featuring an interview with Dr Raajit K Rampal, including the following topics:

  • Clinical decision-making in the initiation and stopping of systemic therapy for myelofibrosis (MF) (0:00)
  • Novel research strategies involving CDK4/6 inhibitors for MF (8:03)
  • Implications of the JUMP study for clinical practice (10:00)
  • Therapeutic switching strategies with JAK inhibitors for MF (12:17)
  • Clinical rationale for the use of luspatercept and elritercept for MF (15:35)
  • Emerging clinical data involving BET inhibitors for MF (16:57)
  • Tolerability concerns with selinexor in patients with MF (20:01)
  • Mechanism of and clinical data with the MDM2 inhibitor navtemadlin for MF (22:32)
  • Additional novel strategies under clinical investigation for MF (25:52)
  • Potential transformation of myeloproliferative neoplasms to acute myeloid leukemia (29:40)
  • Management of polycythemia vera and essential thrombocythemia (34:27)
  • General management principles for myeloproliferative neoplasms (37:53)

CME information and select publications

  continue reading

1554 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide

Listen to this show while you explore
Play